Drug specific resistance to oxaliplatin is associated with apoptosis defect in a cellular model of colon carcinoma

FEBS Letters

Volumn 529, Issue 2-3, 2002, Pages 232-236

  Gourdier, Isabelle ^a   Del Rio, Maguy ^a   Crabbé, Laure ^a   Candeil, Laurent ^a   Copois, Virginie ^a   Ychou, Marc ^b   Auffray, Charles ^a   Martineau, Pierre ^a   Mechti, Nadir ^a   Pommier, Yves ^c   Pau, Bernard ^a  

^a CNRS   (France)

^b CENTRE VAL D AURELLE   (France)

^c NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Apoptosis; Bax; Colorectal cancer; Drug resistance; Oxaliplatin

Indexed keywords

ARSENIC TRIOXIDE; CASPASE 3; CISPLATIN; IRINOTECAN; LONIDAMINE; OXALIPLATIN; PROTEIN BAX;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER MODEL; CANCER RESISTANCE; CELL CLONE; CELL FUNCTION; COLON CARCINOMA; CONTROLLED STUDY; ENZYME ACTIVATION; FLUORESCENCE ACTIVATED CELL SORTING; FRAMESHIFT MUTATION; HUMAN; HUMAN CELL; MITOCHONDRION; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS; APOPTOSIS; ARSENICALS; BASE SEQUENCE; BLOTTING, WESTERN; CASPASE 3; CASPASES; COLONIC NEOPLASMS; DNA PRIMERS; DRUG RESISTANCE, NEOPLASM; FLOW CYTOMETRY; HUMANS; INDAZOLES; MODELS, BIOLOGICAL; ORGANOPLATINUM COMPOUNDS; OXIDES; PROTO-ONCOGENE PROTEINS C-BCL-2;

EID: 18644383632     PISSN: 00145793     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-5793(02)03347-1     Document Type: Article

References (24)

1. Bonithon-Kopp C., Benhamiche A.M. Eur. J. Cancer Prev. 8:(Suppl. 1):1999;S3-12.
2. Greenlee R.T., Murray T., Bolden S., Wingo P.A. CA Cancer J. Clin. 50:2000;7-33.
3. Napier M.P., Ledermann J.A. Eur. J. Surg. Oncol. 26:2000;605-610.
4. Waters J., Cunningham D. Br. J. Cancer. 84:2001;1-7.
5. Culy C.R., Clemett D., Wiseman L.R. Drugs. 60:2000;895-924.
6. Kelland, L.R. (2000) Drugs 59, 1-8; discussion 37-38.
7. Woynarowski J.M., et al. Mol. Pharmacol. 58:2000;920-927.
8. Ferry K.V., Hamilton T.C., Johnson S.W. Biochem. Pharmacol. 60:2000;1305-1313.
9. Fink D., Nebel S., Aebi S., Zheng H., Cenni B., Nehme A., Christen R.D., Howell S.B. Cancer Res. 56:1996;4881-4886.
10. Raymond E., Faivre S., Woynarowski J.M., Chaney S.G. Semin. Oncol. 25:1998;4-12.
11. Vaisman A., Varchenko M., Umar A., Kunkel T.A., Risinger J.I., Barrett J.C., Hamilton T.C., Chaney S.G. Cancer Res. 58:1998;3579-3585.
12. El-akawi Z., Abu-hadid M., Perez R., Glavy J., Zdanowicz J., Creaven P.J., Pendyala L. Cancer Lett. 105:1996;5-14.
13. Hector S., Bolanowska-Higdon W., Zdanowicz J., Hitt S., Pendyala L. Cancer Chemother. Pharmacol. 48:2001;398-406.
14. Vermes I., Haanen C., Steffens-Nakken H., Reutelingsperger C. J. Immunol. Methods. 184:1995;39-51.
15. Ionov Y., Yamamoto H., Krajewski S., Reed J.C., Perucho M. Proc. Natl. Acad. Sci. USA. 97:2000;10872-10877.
16. Rixe O., Ortuzar W., Alvarez M., Parker R., Reed E., Paull K., Fojo T. Biochem. Pharmacol. 52:1996;1855-1865.
17. Ravagnan L., et al. Oncogene. 18:1999;2537-2546.
18. Larochette N., et al. Exp. Cell Res. 249:1999;413-421.
19. Green D.R., Reed J.C. Science. 281:1998;1309-1312.
20. Slee E.A., Adrain C., Martin S.J. Cell Death Differ. 6:1999;1067-1074.
21. Zhang L., Yu J., Park B.H., Kinzler K.W., Vogelstein B. Science. 290:2000;989-992.
22. Kroemer G., Reed J.C. Nature Med. 6:2000;513-519.
23. Reed J.C. J. Clin. Oncol. 17:1999;2941-2953.
24. Nicholson D.W. Nature. 407:2000;810-816.